WO2003095455A2 - Substituted pyrazolopyrimidines - Google Patents
Substituted pyrazolopyrimidines Download PDFInfo
- Publication number
- WO2003095455A2 WO2003095455A2 PCT/US2003/013395 US0313395W WO03095455A2 WO 2003095455 A2 WO2003095455 A2 WO 2003095455A2 US 0313395 W US0313395 W US 0313395W WO 03095455 A2 WO03095455 A2 WO 03095455A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- het
- group
- formula
- compound
- compound according
- Prior art date
Links
- 0 CC(C=CC=CC=C(C=CC=C1)c2n[n]3c(*I)ccnc3c2*)=C2C1=C2 Chemical compound CC(C=CC=CC=C(C=CC=C1)c2n[n]3c(*I)ccnc3c2*)=C2C1=C2 0.000 description 3
- OGTFAWIBGGVIGH-UHFFFAOYSA-N Fc1nccc(-c2c3nccc(N4CCCC4)[n]3nc2-c2ccccc2)c1 Chemical compound Fc1nccc(-c2c3nccc(N4CCCC4)[n]3nc2-c2ccccc2)c1 OGTFAWIBGGVIGH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- the present invention relates to novel compounds, pharmaceutical formulations comprising these compounds, and the use of these compounds in therapy. More particularly, the present invention relates to compounds for the prophylaxis and treatment of herpes viral infections.
- herpes group are the sources of the most common viral illnesses in man.
- the group includes herpes simplex virus types 1 and 2 (HSV), varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpes virus type 6 (HHV-6), human herpes virus type 7 (HHV-7) and human herpes virus type 8 (HHV-8).
- HSV-1 and HSV-2 are some of the most common infectious agents of man. Most of these viruses are able to persist in the host's neural cells; once infected, individuals are at risk of recurrent clinical manifestations of infection which can be both physically and psychologically distressing.
- Herpes simplex viruses are the causative agents of herpes labialis and genital herpes. HSV infection is often characterised by extensive and debilitating lesions of the skin, mouth and/or genitals. Primary infections may be subclinical although tend to be more severe than infections in individuals previously exposed to the virus. Ocular infection by HSV can lead to keratitis or cataracts thereby endangering the host's sight. Infection in the new-born, in immunocompromised patients or penetration of the infection into the central nervous system can prove fatal. In the US alone, 4-0 million individuals are infected with HSV-2, a number that is expected to increase to 60 million by 2007.
- VZV Varicella zoster virus
- Hupox is the primary disease produced in a host without immunity, and in young children is usually a mild illness characterised by a vesicular rash and fever.
- Shingles or zoster is the recurrent form of the disease which occurs in adults who were previously infected with VZV.
- the clinical manifestations of shingles are characterised by neuralgia and a vesicular skin rash that is unilateral and dermatomal in distribution. Spread of inflammation may lead to paralysis or convulsions. Coma can occur if the meninges become affected.
- VZV is of serious concern in patients receiving immunosuppressive drugs for transplant purposes or for treatment of malignant neoplasia and is a serious complication of AIDS patients due to their impaired immune system.
- CMV infection In common with other herpes viruses, infection with CMV leads to a lifelong association of virus and host. Congenital infection following infection of the mother during pregnancy may give rise to clinical effects such as death or gross disease (microcephaly, hepatosplenomegaly, jaundice, mental retardation), retinitis leading to blindness or, in less severe forms, failure to thrive, and susceptibility to chest and ear infections. CMV infection in patients who are immunocompromised for example as a result of malignancy, treatment with immunosuppressive drugs following transplantation or infection with Human Immunodeficiency Virus, may give rise to retinitis, pneumonitis, gastrointestinal disorders and neurological diseases. CMV infection is also associated with cardiovascular diseases and conditions including restenosis and atherosclerosis.
- EBV infectious mononucleosis
- diseases include lymphoproliferative disease which frequently occurs in persons with congenital or acquired cellular immune deficiency, X-linked lymphoproliferative disease which occurs namely in young boys, EBV-associated B-cell tumours, Hodgkin's disease, nasopharyngeal carcinoma, Burkitt lymphoma, non-Hodgkin lymphoma, thymomas and oral hairy leukoplakia.
- EBV infections have also been found in association with a variety of epithelial-cell-derived tumours of the upper and lower respiratory tracts including the lung. EBV infection has also been associated with other diseases and conditions including chronic fatigue syndrome, multiple sclerosis and Alzheimer's disease.
- HHV-6 has been shown to be a causative agent of infantum subitum in children and of kidney rejection and interstitial pneumonia in kidney and bone marrow transplant patients, respectively, and may be associated with other diseases such as multiple sclerosis. There is also evidence of repression of stem cell counts in bone marrow transplant patients. HHV-7 is of undetermined disease aetiology.
- Hepatitis B virus is a viral pathogen of world-wide major importance.
- the virus is aetiologically associated with primary hepatocellular carcinoma and is thought to cause 80% of the world's liver cancer.
- Clinical effects of infection with HBV range from headache, fever, malaise, nausea, vomiting, anorexia and abdominal pains.
- Replication of the virus is usually controlled by the immune response, with a course of recovery lasting weeks or months in humans, but infection may be more severe leading to persistent chronic liver disease outlined above.
- each R 1 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalky), cycloalkenyl, Ay, Het, -C(0)R 9 , -C(0)Ay, -C(0)Het, -CO2R 9 , -C(0)NR 7 R 8 , -C(0)NR 7 Ay, -C(S)NR 9 R 11 ,
- each R 7 and R 8 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -C(0)R 9 , -CO2R 9 , -C(0)NR 9 R 11 , -C(S)NR 9 R", -C(NH)NR 9 R", -SO2R 10 ,
- each R 9 and R 11 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, -R 10 cycloalkyl, -R'°0H, -R ,0 (0R'°)w where w is 1 -10, and -R
- Het is a 5- or 6-membered heterocyclic or heteroaryl group; n is 0, 1 or 2;
- Y is N or CH
- R 2 is selected from the group consisting of Ay, Het, -OAy, -OHet, -OR 10 Ay, -OR 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0)nR 9 , -S(0) ⁇ Ay, -R 10 NR 7 R 8 and -R 10 NR 7 Ay;
- R 3 and R 4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, -C(0)R 7 , -C(0)Ay, -C0 2 R 7 , -C0 2 Ay, -OR 7 , -OAy, -0R 10 Ay, -OR 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -SO2NHR 9
- a pharmaceutical composition comprising a compound of formula (I).
- the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition further comprises an antiviral agent selected from the group consisting of aciclovir and valaciclovir.
- a method for the prophylaxis or treatment of a herpes viral infection in an animal comprises administering to the animal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
- the herpes viral infection can be any of herpes simplex virus 1, herpes simplex virus 2, cytomegalovirus, Epstein Barr virus, varicella zoster virus, human herpes virus 6, human herpes virus 7, and human herpes virus 8.
- a method for the prophylaxis or treatment of a condition or disease associated with a herpes viral infection in an animal comprises administering to the animal a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
- the present invention provides a radiolabeled compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
- the present invention provides a tritiated compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
- the present invention provides a biotinylated compound of formula (I) or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
- the present invention provides a compound of formula (I) for use in therapy.
- the present invention provides a compound of formula (I) for use in the prophylaxis or treatment of a herpes viral infection.
- the present invention provides a compound of formula (I) for use in the prophylaxis or treatment of a condition or disease associated with a herpes viral infection in an animal.
- the present invention provides the use of a compound of formula (I) for the preparation of a medicament for the prophylaxis or treatment of a herpes viral infection in animal, particularly humans.
- the present invention provides the use of a compound of formula (I) for the preparation of a medicament for the treatment or prophylaxis of diseases or conditions associated with a herpes viral infection in animals, preferrably humans.
- a compound of the invention or "a compound of formula (I)” means a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
- a compound of formula (number) means a compound having that formula and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.
- alkyl refers to straight or branched hydrocarbon chains containing from 1 to 8 carbon atoms.
- alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl, and tert-butyl.
- alkylene as used herein include, but are not limited to, methylene, ethylene, propylene, butylene, and isobutylene.
- Alkyl also includes substituted alkyl. The alkyl groups may be optionally substituted with one or more substituents selected from the group consisting of mercapto, nitro, cyano and halo. Perhaloalkyl, such as trifluoromethyl is one particular alkyl group.
- cycloalkyl refers to a non-aromatic carbocyclic ring having from 3 to 8 carbon atoms and no carbon-carbon double bonds.
- Cycloalkyl includes by way of example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- Cycloalkyl also includes substituted cycloalkyl.
- the cycloalkyl may be optionally substituted on an available carbon with one or more substituents selected from the group consisting of mercapto, nitro, cyano, halo and alkyl.
- alkenyl refers to straight or branched hydrocarbon chains containing from 2 to 8 carbon atoms and at least one and up to three carbon-carbon double bonds. Examples of “alkenyl” as used herein include, but are not limited to ethenyl and propenyl. "Alkenyl” also includes substituted alkenyl. The alkenyl groups may optionally be substituted on an available carbon with one or more substituents selected from the group consisting of mercapto, nitro, cyano, halo and alkyl.
- cycloalkenyl refers to a non-aromatic carbocyclic ring having from 3 to 8 carbon atoms (unless otherwise specified) and up to 3 carbon- carbon double bonds.
- Cycloalkenyl includes by way of example cyclobutenyl, cyclopentenyl and cyclohexenyl.
- Cycloalkenyl also includes substituted cycloalkenyl.
- the cycloalkenyl may optionally be substituted on an available carbon with one or more substituents selected from the group consisting of mercapto, nitro, cyano, halo and alkyl.
- alkynyl refers to straight or branched hydrocarbon chains containing from 2 to 8 carbon atoms and at least one and up to three carbon-carbon triple bonds. Examples of “alkynyl” as used herein include, but are not limited to ethynyl and propynyl. "Alkynyl” also includes substituted alkynyl. The alkynyl groups may optionally be substituted on an available carbon with one or more substituents selected from the group consisting of mercapto, nitro, cyano, halo and alkyl.
- halo or halogen refers to the elements fluorine, chlorine, bromine and iodine.
- aryl refers to monocyclic carbocyclic groups and fused bicyclic carbocyclic groups having from 5 to 12 carbon atoms and having at least one aromatic ring. Examples of particular aryl groups include but are not limited to phenyl, and naphthyl. "Aryl” also includes substituted aryl.
- Aryl groups may optionally be substituted on an available carbon with one or more substituents selected from the group consisting of halo, alkyl (including perhaloalkyl), alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, amino, mercapto, hydroxy, alkylhydroxy, alkylamine, cycloalkylamine, carboxy, carboxamide, sulfonamide, Het, amidine, cyano, nitro and azido.
- substituents selected from the group consisting of halo, alkyl (including perhaloalkyl), alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, amino, mercapto, hydroxy, alkylhydroxy, alkylamine, cycloalkylamine, carboxy, carboxamide, sulfonamide, Het, amidine, cyano, nitro and azido.
- heterocyclic refers to a monocyclic saturated or unsaturated non-aromatic groups and fused bicyclic non-aromatic groups, having the specified number of members and containing 1 , 2, 3 or 4 heteroatoms selected from N, O and S.
- heterocyclic groups include but are not limited to tetrahydrofuran, dihydropyran, tetra hydro pyran, pyran, oxetane, thietane, 1 ,4-dioxane, 1 ,3-dioxane, 1,3-dioxalane, piperidine, piperazine, tetrahydropyrimidine, pyrrolidine, morpholine, thiomorpholine, thiazolidine, oxazolidine, tetrahydrothiopyran, tetrahydrothiophene, and the like.
- Heterocyclic also includes substituted heterocyclic.
- the heterocyclic groups may optionally be substituted on an available carbon or heteroatom with one or more substituents selected from the group consisting of halo, alkyl (including perhaloalkyl), alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, amino, mercapto, hydroxy, alkylhydroxy, alkylamine, cycloalkylamine, carboxy, carboxamide, sulfonamide, Het, amidine, cyano, nitro and azido.
- substituents selected from the group consisting of halo, alkyl (including perhaloalkyl), alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, amino, mercapto, hydroxy, alkylhydroxy, alkylamine, cycloalkylamine, carboxy, carboxamide, sulfonamide, Het, amidine, cyano, nitro and azid
- heteroaryl refers to aromatic monocyclic groups and aromatic fused bicyclic groups (having at least one aromatic ring) having the specified number of members and containing 1, 2, 3, or 4 heteroatoms selected from N, 0 and S.
- heteroaryl groups include but are not limited to furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, and indazole.
- Heteroaryl also includes substituted heteroaryl.
- the heteroaryl groups may optionally be substituted on an available carbon or heteroatom with one or more substituents selected from the group consisting of halo, alkyl (including perhaloalkyl), alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, amino, mercapto, hydroxy, alkylhydroxy, alkylamine, cycloalkylamine, carboxy, carboxamide, sulfonamide, Het, amidine, cyano, nitro and azido.
- Particular heteroaryl groups according to the invention include but are not limited to pyridine, furan, thiophene, pyrrole, imidazole, pyrazole and pyrimidine, and substituted variants thereof.
- heterocyclic and heteroaryl groups refers to the total atoms, carbon and heteroatoms N, 0 and/or S, which form the ring.
- a 6-membered heterocyclic ring is piperidine and an example of a 6-membered heteroaryl ring is pyridine.
- the term "optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) that occur and events that do not occur.
- the present invention provides compounds of formula (I):
- each R is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(0)R 9 , -C(0)Ay, -C(0)Het, -C0 2 R 9 , -C(0)NR 7 R 8 , -C(0)NR 7 Ay, -C(S)NR 9 R 11 , -C(NH)NR 7 R 8 , -C(NH)NR 7 Ay, -OR 7 , -OAy, -OHet, -0R 10 Ay, -OR 10 Het, -NR 7 R 8 , -NR Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0) ⁇ R 9 , -S(0) ⁇ Ay, -S(0) n Het,
- each R 9 and R" are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, -R 10 cycloal yl, -R 10 OH, -R 10 (OR 10 )w where w is 1-10, and -R 10 NR 10 R 10 ; each R 10 is the same or different and is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl; Ay is aryl;
- Het is a 5- or 6-membered heterocyclic or heteroaryl group; n is O, 1 or 2; Y is N or CH;
- R 2 is selected from the group consisting of Ay, Het, -OAy, -OHet, -0R 10 Ay, -0R 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0) consentR 9 , -S(0)nAy, -R 10 NR 7 R 8 and -R 10 NR 7 Ay;
- R 3 and R 4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, -C(0)R 7 , -C(0)Ay,
- Ring A is selected from the group consisting of aryl, 5-10 membered heterocyclic group and a 5-10 membered heteroaryl group; q is 0, 1, 2, 3, 4 or 5; and each R 5 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -C(0)R 9 , -C(0)Ay, -C(0)Het, -C0_R 9
- -R 10 cycloalkyl, -R 10 Het, -R 10 C(O)R 9 , -R 10 CO 2 R 9 , -R 10 C(0)NR 9 R n , -R 10 C(O)NR 7 Ay, -R 10 C(O)NHR l0 Het, -R 10 C(S)NR 9 R 11 , - 10 C(NH)NR 9 R 11 , -R 10 OR 9 , -R 10 NR 7 R 8 , -R 10 NR 7 Ay, -R 10 S0 2 R 9 , -R 10 S02NR 9 R 11 , -R 10 S0 2 NHC0R 9 , cyano, nitro and azido; and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof.
- p is 1 or 2. In one particular embodiment, p is 1.
- R 1 may be at the C-5, C-6 and/or C-7 positions.
- Compounds of formula (I) include those compounds defined wherein at least one R 1 contains an aryl, heterocyclic or heteroaryl moiety.
- Ay, Het, -C(0)Ay, -C(0)Het, -C(0)NR 7 Ay, -C(NH)NR 7 Ay, -OAy, -OHet, -OR 10 Ay, -OR 10 Het, -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0) ⁇ Ay, -S(0) n Het, -S(0) 2 NR 7 Ay, -R 10 Ay, -R ,0 NR 7 Ay, -R 10 C(O)Ay, -R 10 C(O)Het, -R'°OC(0)Ay, -R ,0 OC(0)Het, -R 10 C(0)NR 7 Ay and -R 10 C(0)NHR 10 Het, are examples of groups containing an
- the compounds of the present invention include those compounds defined wherein at least one R 1 contains a heterocyclic or heteroaryl moiety such as Het, -C(0)Het, -OHet, -OR 10 Het, -NHHet, -NHR 10 Het, -S(0)nHet, -R 10 C(0)Het, -R 10 0C(0)Het and -R 10 C(O)NHR 10 Het.
- R 1 contains a heterocyclic or heteroaryl moiety such as Het, -C(0)Het, -OHet, -OR 10 Het, -NHHet, -NHR 10 Het, -S(0)nHet, -R 10 C(0)Het, -R 10 0C(0)Het and -R 10 C(O)NHR 10 Het.
- Another class of compounds of formula (I) includes those compounds defined wherein R 1 does not contain an aryl, heterocyclic or heteroaryl moiety.
- R 1 is typically halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, -C(0)R 9 , -C0_R 9 , -C(0)NR R 8 , ⁇ C(S)NR 9 R 1 ⁇ -C(NH)NR 7 R 8 , -OR 7 , -NR 7 R 8 , -S(0) n R 9 , -S(0) 2 NR 7 R 8 , -R 10 cycloalkyl, -R 10 OR 9 , -R 10 NR 7 R 8 , -R 10 NHSO 2 R 9 , -R 10 C(O)R 9 , -R 10 CO 2 R 9 , -R 10 0C(O)R 9 , -R 10 C(0)NR 9 R n , -R ⁇ C.SJ R ⁇ 11 , -R 10 C(NH)NR 9 R 11 , -R 10 S0 2 R 9 , ,
- R 1 does not contain a heterocyclic or heteroaryl moiety but may contain an aryl moiety.
- R 1 is typically selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, -C(0)R 9 , -C(0)Ay, -CO2R 9 , -C(0)NR 7 R 8 , -C(0)NR 7 Ay, -C(S)NR 9 R 11 , -C(NH)NR 7 R 8 , -C(NH)NR 7 Ay, -OR 7 , -OAy, -0R ,0 Ay, -NR 7 R 8 , -NR 7 Ay, -NHR 1Q Ay, -S(0) consentR 9 , -S(0) ⁇ Ay, -S(0) 2 NR 7 R 8 , -S(0)_NR 7 Ay, -R 10 cycl
- R 1 is at the C-7 position.
- each R 1 is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, Ay, Het, -OR 7 , -OAy, -OHet, -OR 10 Ay, -OR 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR ,0 Ay, -NHR 10 Het, -S(0) n R 9 , -S(0) ⁇ Ay, -S(0)nHet, -S(0) 2 NR 7 R 8 , -S(0) 2 NR 7 Ay, cyano, nitro and azido, or any subset thereof.
- each R 1 is the same or different and is independently selected from the group consisting of halo, Ay, Het, -NR 7 R 8 , -NHHet, -S(0)nR 9 , -S(0)nAy, and cyano, or any subset thereof.
- each R 1 is the same or different and is independently selected from the group consisting of halo, Ay, Het and -NR 7 R 8 , or any subset thereof.
- each R 1 may be the same or different and is independently selected from the group consisting of Cl, Ay, -NH 2 , -NH-alkyl, -NH- cycloalkyl, -N(alkyl).alkyl), Het, -Nalkyl-O-alkyl, and NHAy, or any subset thereof.
- R 1 groups are selected from the group consisting of Cl, phenyl, -NH_, -NH-methyl, -N(CH 3 ) 2 , -NH-cyclopentyl, -NH-cyclopropyl, -NH-isopropyl, -NH-phenyl, -N(CH 2 ) 2 0CH3, and pyrrolidine, or any subset thereof.
- Y is CH. In another class of compounds of formula (I), Y is N.
- the compounds of formula (I) include those compounds defined where at least one R 2 contains an aryl, heterocyclic or heteroaryl moiety.
- a further embodiment includes those compounds of formula (I) where no R 2 contains a heterocyclic or heteroaryl moiety.
- no R 2 contains an aryl, heterocyclic or heteroaryl moiety. From the embodiments described above with respect to R 1 , one skilled in the art can readily determine the groups defining R 2 which contain or exclude aryl, heterocyclic and/or heteroaryl moieties.
- R 2 is selected from the group consisting of Het, -NR 7 R 8 , -NR 7 Ay, -NHHet and -S(0)nR 9 , or any subset thereof. More particularly, R 2 is selected from the group consisting of Het, -NR 7 R 8 , -NR 7 Ay and -S(0) n R 9 , or any subset thereof. In one embodiment, R 2 is selected from the group consisting of Het and -NR 7 R 8 . In another embodiment, R 2 is -NR 7 R 8 . In another particular embodiment, R 2 is -NR 7 -cycloalkyl.
- R 2 is selected from the group consisting of -NH_, -NH-alkyl, -NH-cycloalkyl, -N(alk ⁇ !(alkyl), Het (e.g., pyrrolidine), -NHHet and -NH- alkyl-Het, or any subset thereof. More particularly, R 2 is selected from the group consisting of -NH-alkyl and -NH-cycloalkyl, or any subset thereof.
- R 2 groups are selected from the group consisting of -NH 2 , -NH-methyl, -NH-ethyl, -NH-propyl, -NH-isopropyl, -NH-cyclopropyl, -NH-butyl, -NH-isobutyl, -NH-cyclobutyl, -NH-cyclopentyl, -NH-cyclohexyl, -NH(CH 2 )2 ⁇ CH 3 , and pyrrolidine (e.g., pyrrolidine bonded through N).
- R 2 is -NH-cyclopentyl.
- R 7 and R 8 are each the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, R 10 -cycloalkyl, -R 10 0R 9 , -R 10 NR 9 R", -C(0)R 9 , and R 10 C0 2 R 9 , or any subset thereof. More particularly, R 7 and R 8 are each the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl and R 10 -cycloalkyl, or any subset thereof. In one embodiment, R 7 and R 8 are each the same or different and are independently selected from the group consisting of H, alkyl and cycloalkyl or any subset thereof.
- R 9 and R 11 refers to a linear PEG-like chain.
- R 9 and R 11 are each the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, and -R 10 -cycloa)kyl, or any subset thereof. More particularly, R 9 and R 11 are each the same or different and are each independently selected from the group consisting of H and alkyl, or any subset thereof.
- R 10 is alkyl or cycloalkyl; more particularly alkyl.
- the compounds of formula (I) include those compounds defined where at least one of R 3 and R 4 contains a heterocyclic or heteroaryl moiety.
- a further embodiment includes those compounds of formula (l) where neither R 3 nor R 4 contain a heterocyclic or heteroaryl moiety. From the embodiments described above with respect to R ⁇ one skilled in the art can readily determine the groups defining R 3 and R 4 which contain or exclude aryl, heterocyclic and/or heteroaryl moieties.
- R 3 is selected from the group consisting of H, halo, alkyl, Ay, -OR 7 , -C0 2 R 7 , -NR 7 R 8 , -R 10 0R 7 and -R 10 NR 7 R 8 , or any subset thereof. More particularly, R 3 is selected from the group consisting of H, halo, alkyl, -OR 7 and -NR 7 R 8 , or any subset thereof. In one particular embodiment R 3 is H or alkyl. In one embodiment R 3 is H.
- R 4 is selected from the group consisting of H, halo, alkyl, Ay, -OR 7 , -C0 2 R 7 , -NR 7 R 8 , -R 10 0R 7 and -R 10 NR 7 R 8 , or any subset thereof. More particularly R 4 is selected from the group consisting of H, halo, alkyl, OR 7 and -NR 7 R 8 , or any subset thereof. In one particular embodiment, R 4 is H or alkyl. In one embodiment R 4 is H.
- Ring A is herein referred to as "Ring A.”
- Ring A is aryl, a 5-10 membered heterocyclic group (including a 1, 2, 3 or 4 heteroatoms selected from N, 0 and S) or a 5-10 membered heteroaryl group (including 1, 2, 3 or 4 heteroatoms selected from N, 0 and S). Ring A may be bonded to the C-2 carbon of the fused ring through any suitable atom including any suitable heteroatom. In one particular embodiment, Ring A is selected from the group consisting of aryl, a 5-10 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, 0 and S and a 5-10 membered heteroaryl group containing 1 , 2 or 3 heteroatoms selected from N, 0 and S.
- Ring A is selected from the group consisting of aryl, a 5-6 membered heterocyclic or heteroaryl group and a 9-membered heterocyclic or heteroaryl group. In one particular embodiment, Ring A is selected from the group consisting of aryl; a 5-6 membered heterocyclic or heteroaryl group containing 1 , 2 or 3 heteroatoms selected from N, 0 and S; and a 9-membered heterocyclic or heteroaryl group containing 1 , 2 or 3 heteroatoms selected from N, 0 and S.
- Ring A is selected from the group consisting of phenyl, naphthyl, furan, pyridine, pyrimidine, thiazole, pyrazine, pyrrole, imidazole, oxazole, benzimidazole, quinoline, isoquinoline, and quinoxoline, or any subset thereof. More particualrly, Ring A in formula (I) is selected from the group consisting of phenyl, furan, pyridine and pyrimidine. In one embodiment, Ring A contains at least one N atom and is bonded through N. In another embodiment, Ring A is phenyl.
- q is 0, 1 or 2. In one particular embodiment, q is 0. In another particular embodiment, q is 1. In one embodiment, q is 2.
- R 5 may be in the ortho, eta and/or para position.
- One class of compounds of formula (I) includes those compounds defined wherein at least one R 5 group contains an aryl, heterocyclic or heteroaryl moiety (in one embodiment, a heterocyclic or heteroaryl moiety).
- Another class of compounds of formula (I) includes those compounds defined wherein no R 5 group contains an aryl, heterocyclic or heteroaryl moiety (or in one embodiment no R s group contains a heterocyclic or heteroaryl moeity).
- each R 5 group is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, Ay, Het, -CO2R 9 , -C(0)NR 7 R 8 , -OR 7 , -OAy, -NR 7 R 8 , -NR 7 Ay, -S(0) 2 NR 7 R 8 , cyano, nitro and azido, or any subset thereof.
- each R 5 group is the same or different and is independently selected from the group consisting of halo, alkyl, alkenyl, Ay, Het, -OR 7 , -NR 7 R 8 , -NR 7 Ay, cyano, nitro and azido, or any subset thereof.
- each R 5 group is the same or different and is independently selected from the group consisting of halo, alkyl, -OR 7 , -NR 7 R 8 and cyano, or any subset thereof.
- each R 5 is the same or different and is independently selected from the group consisting of H, halo (e.g., fluoro, chloro or bromo), alkyl (e.g., methyl), O-alkyl (e.g., O-methyl, 0-isobutyl, and " ° '' ⁇ ⁇
- halo e.g., fluoro, chloro or bromo
- alkyl e.g., methyl
- O-alkyl e.g., O-methyl, 0-isobutyl, and " ° '' ⁇ ⁇
- cyano e.g., cyano, -NH-CHs, and -N(CH 3 ) 2l or any subset thereof.
- Specific compounds of formula (I) include but are not limited to: 3-(2-Fluoropyridin-4-yl)-2-phenyl-7-pyrrolidin-1-ylpyrazolo_1,5- ⁇ ]pyrimidine; ⁇ /-Cyclopentyl-4-(2-phenyl-7-pyrrolidin-1-ylpyrazolo[l ,5- ⁇ ]pyrimidin-3-yl)pyridin-2- a ine; >
- the compounds of the present invention may also be utilized in the form of a pharmaceutically acceptable salt or solvate or physiologically functional derivative thereof.
- the pharmaceutically acceptable salts of the compounds of formula (I) include conventional salts formed from pharmaceutically acceptable inorganic or organic acids or bases as well as quaternary ammonium salts.
- suitable acid salts include hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, palmoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzole, salicylic, fumaric, toluenesulfonic, methanesulfonic (mesylate), naphthalene-2-sulfonic, benzenesulfonic hydroxynaphthoic, hydroiodic, malic, steroic, tannic and the like.
- the compounds of formula (I) are in the form of the mesylate salt.
- Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable salts.
- More specific examples of suitable basic salts include sodium, lithium, potassium, magnesium, aluminium, calcium, zinc, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine and procaine salts.
- solvate refers to a complex of variable stoichiometry formed by a solute (a compound of formula (I)) and a solvent.
- Solvents include water, methanol, ethanol, or acetic acid.
- physiologically functional derivative refers to any pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide of a compound of formula (I), which upon administration to an animal, particularly a mammal, such as a human, is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. See, for example, Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1 : Principles And Practice.
- Processes for preparing pharmaceutically acceptable salts, solvates and physiologically functional derivatives of the compounds of formula (I) are conventional in the art. See, e.g., Burger's Medicinal Chemistry And Drug Discovery 5th Edition, Vol 1 : Principles And Practice. As will be apparent to those skilled in the art, in the processes described below for the preparation of compounds of formula (I), certain intermediates, may be in the form of pharmaceutically acceptable salts, solvates or physiologically functional derivatives of the compound. Those terms as applied to any intermediate employed in the process of preparing compounds of formula (I) have the same meanings as noted above with respect to compounds of formula (I). Processes for preparing pharmaceutically acceptable salts, solvates and physiologically functional derivatives of such intermediates are known in the art and are analogous to the process for preparing pharmaceutically acceptable salts, solvates and physiologically functional derivatives of the compounds of formula (I).
- Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism).
- the individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention.
- the present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted.
- compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.
- the present invention further provides compounds of formula (I) for use in medical therapy, e.g. in the treatment or prophylaxis, including suppression of recurrence of symptoms, of a viral disease in an animal, e.g. a mammal such as a human.
- the compounds of formula (I) are especially useful for the treatment or prophylaxis of viral diseases such as herpes viral infections.
- Herpes viral infections include, for example, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), cytomegalovirus (CMV), Epstein Barr virus (EBV), varicella zoster virus (VZV), human herpes virus 6 (HHV-6), human herpes virus 7 (HHV-7), and human herpes virus 8 (HHV-8).
- HSV-1 herpes simplex virus 1
- HSV-2 herpes simplex virus 2
- CMV cytomegalovirus
- EBV Epstein Barr virus
- VZV varicella zoster virus
- human herpes virus 6 HHV-6
- human herpes virus 7 HHV-7
- HHV-8 human herpes virus 8
- the compounds of the invention are also useful in the treatment or prophylaxis of the symptoms or effects of herpes virus infections.
- the compounds of the invention are useful in the treatment or prophylaxis of conditions or diseases associated with herpes virus infections, particularly conditions or
- conditions or diseases associated with herpes viral infections is meant a condition or disease, excluding the viral infection per se, which results from the presence of the viral infection, such as chronic fatigue syndrome which is associated with EBV infection; and multiple sclerosis which has been associated with herpes viral infections such as EBV and HHV-6. Further examples of such conditions or diseases are described in the background section above.
- the compounds of the present invention may also be used for the treatment or prophylaxis of cardiovascular diseases and conditions associated with herpes virus infections, in particular atherosclerosis, coronary artery disease and restenosis and specifically restenosis following angioplasty (RFA).
- Restenosis is the narrowing of the blood vessels which can occur after injury to the vessel wall, for example injury caused by balloon angioplasty or other surgical and/or diagnostic techniques, and is characterized by excessive proliferation of smooth muscle cells in the walls of the blood vessel treated. It is thought that in many patients suffering from RFA, viral infection, particularly by CMV and/or HHV-6 of the patient plays a pivotal role in the proliferation of the smooth muscle cells in the coronary vessel treated. Restenosis can occur following a number of surgical and/or diagnostic techniques, for example, transplant surgery, vein grafting, coronary by-pass grafting and, most commonly following angioplasty.
- vascular smooth muscle cells SMC
- extracellular matrix material which accumulate to occlude the blood vessel.
- growth suppressors act to inhibit the proliferation of SMC's and production of extracellular matrix material.
- compounds of formula (I) may be useful in the treatment or prophylaxis of conditions or diseases associated with hepatitis B or hepatitis C viruses, human papilloma virus (HPV) and HIV.
- the present invention provides a method for the treatment or prophylaxis of a viral infection in an animal such as a mammal (e.g., a human), particularly a herpes viral infection, which method comprises administering to the animal a therapeutically effective amount of the compound of formula (I).
- prophylaxis refers to the prevention of infection, the prevention of occurrence of symptoms in an infected subject, the prevention of recurrence of symptoms in an infected subject, or a decrease in severity or frequency of symptoms of viral infection, condition or disease in the subject.
- treatment refers to the partial or total elimination of symptoms or decrease in severity of symptoms of viral infection, condition or disease in the subject, or the elimination or decrease of viral presence in the subject.
- terapéuticaally effective amount means an amount of a compound of formula (I) which is sufficient, in the subject to which it is administered, to treat or prevent the stated disease, condition or infection.
- a therapeutically effective amount of a compound of formula (I) for the treatment of a herpes virus infection is an amount sufficient to treat the herpes virus infection in the subject.
- the present invention also provides a method for the treatment or prophylaxis of a condition or disease associated with herpes viral infections in an animal such as a mammal (e.g., a human), which comprises administering to the animal a therapeutically effective amount of the compound of formula (I).
- the present invention provides a method for the treatment or prophylaxis of chronic fatigue syndrome and multiple sclerosis in an animal such as a mammal (e.g., a human), which comprises administering to the animal a therapeutically effective amount of a compound of formula (I).
- the foregoing method is particularly useful for the treatment or prophylaxis of chronic fatigue syndrome and multiple sclerosis associated with latent infection with a herpes virus.
- the present invention provides a method for the treatment or prophylaxis of a cardiovascular condition such as atherosclerosis, coronary artery disease or restenosis (particularly restenosis following surgery such as angioplasty), which comprises administering to the animal a therapeutically effective antiviral amount of the compound of formula (I).
- a cardiovascular condition such as atherosclerosis, coronary artery disease or restenosis (particularly restenosis following surgery such as angioplasty)
- the present invention further provides a method for the treatment or prophylaxis of hepatitis B or hepatitis C viruses in an animal such as a mammal (e.g., a human), which comprises administering to the animal a therapeutically effective amount of the compound of formula (I).
- a mammal e.g., a human
- the present invention further provides a method for the treatment or prophylaxis of human papilloma virus in an animal such as a mammal (e.g., a human), which comprises administering to the animal a therapeutically effective amount of the compound of formula (I).
- a mammal e.g., a human
- the present invention further provides a method for the treatment or prophylaxis of HIV in an animal such as a mammal (e.g., a human), which comprises administering to the animal a therapeutically effective amount of the compound of formula (I).
- a mammal e.g., a human
- the present invention also provides the use of the compound of formula (1) in the preparation of a medicament for the treatment or prophylaxis of a viral infection in an animal such as a mammal (e.g., a human), particularly a herpes viral infection; the use of the comound of formula (I) in the preparation of a medicament for the treatment of a condition or disease associated with a herpes viral infection; and the use of the compound of formula (I) in the preparation of a medicament for the treatment or prophylaxis of hepatitis B or hepatitis C viruses, human papilloma virus and HIV.
- a mammal e.g., a human
- the present invention also provides the use of a compound of formula (I) in the preparation of a medicament for the treatment or prophylaxis of chronic fatigue syndrome or multiple sclerosis.
- the present invention provides the use of a compound of formula (I) in the preparation of a medicament for the treatment or prophylaxis of cardiovascular disease, such as restenosis and atherosclerosis.
- compositions are conveniently administered in the form of pharmaceutical compositions.
- Such compositions may conveniently be presented for use in conventional manner in admixture with one or more physiologically acceptable carriers or diluents.
- compositions may comprise a pharmaceutically acceptable carrier or diluent.
- carrier(s) or diluent(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the present invention further provides for a pharmaceutical formulation or composition comprising a compound of formula (I).
- the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers or diluents and optionally, other therapeutic and/or prophylactic ingredients.
- the formulations include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intradermal, intrathecal, intramuscular e.g. by depot and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon for example the condition, age, and disorder of the recipient as well as the viral infection or disease being treated.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the compound(s) ("active ingredient”) with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
- Formulations suitable for oral administration may be presented as discrete units such as capsules (including soft-gel capsules), cachets or tablets (e.g. chewable tablets in particular for paediatric administration) each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be presented as a bolus, electuary or paste.
- a tablet may be made by compression or moulding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with other conventional excipients such as binding agents, (for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers (for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl sulfate.
- binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage
- Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.
- the tablets may be coated according to methods well-known in the art.
- the compounds of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, for example.
- formulations containing these compounds may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives such as methyl or propyl p-hydroxybenzoates or sorbic acid.
- suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible fats
- emulsifying agents such as lecithin, sorbitan mono-oleate or acacia
- non-aqueous vehicles which may
- Such preparations may also be formulated as suppositories, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- Liquid preparations may also be formulated as soft-gel capsules for oral administration, e.g., containing conventional soft-gel excipients such as polyethylene glycol.
- Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophi ⁇ sed) condition requiring only the addition of a sterile liquid carrier, for example, water-for-injection, immediately prior to use.
- a sterile liquid carrier for example, water-for-injection
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter, hard fat or polyethylene glycol.
- Formulations suitable for topical (e.g., dermal) or intranasal application include . ointments, creams, lotions, pastes, gels, sprays, aerosols and oils.
- Suitable carriers for such formulations include petroleum jelly, lanolin, polyethyleneglycols, alcohols, and combinations thereof.
- Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured base such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a base such as gelatin and glycerin or sucrose and acacia.
- a flavoured base such as sucrose and acacia or tragacanth
- pastilles comprising the active ingredient in a base such as gelatin and glycerin or sucrose and acacia.
- the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.
- a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses employed for adult human treatment will typically be in the range of 0.02-5000 mg per day, particularly 100-1500 mg per day.
- the desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
- the formulations according to the invention may contain between 0.1-99% of the active ingredient, conveniently from 30-95% for tablets and capsules and 3-50% for liquid preparations.
- the compound of formula (I) for use in the instant invention may be used in combination with other therapeutic agents for example, non-nucleotide reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitors and/or other antiviral agents.
- the invention thus provides in a further aspect the use of a combination comprising a compound of formula (I) with a further therapeutic agent in the treatment of viral infections.
- Particular antiviral agents which may be combined with the compounds of the present invention include aciclovir, valaciclovir, famcyclovir, gancyclovir, docosanol, miribavir, amprenavir, lamivudine, zidovudine, and abacavir and pharmaceutically acceptable salts or solvates thereof.
- Particular antiviral agents for combining with the compounds of the present invention include aciclovir and valaciclovir and pharmaceutically acceptable salts or solvates thereof.
- the present invention provides in a further aspect, a combination comprising a compound of formula (I) and an antiviral agent selected from the group consisting of aciclovir and valaciclovir and pharmaceutically acceptable salts or solvates thereof; the use of such combination in the treatment of viral infections and the preparation of a medicament for the treatment of viral infections, and a method of treating viral infections comprising administering a compound of formula (I) and an antiviral agent selected from the group consisting of aciclovir and valaciclovir and pharmaceutically acceptable salts or solvates thereof.
- the compounds of formula (I) When used in combination with other therapeutic agents, the compounds may be administered either sequentially or simultaneously by any convenient route.
- compositions comprising a combination as defined above optionally together with a pharmaceutically acceptable carrier or diluent comprise a further aspect of the invention.
- the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
- the two compounds When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation and may be formulated for administration. When formulated separately they may be provided in any convenient formulation, in such a manner as are known for such compounds in the art.
- each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
- R r is selected from the group consisting of Het, -OR 7 , -OAy, -OHet, -OR 10 Ay,
- each R 7 and R 8 are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, -C(0)R 9 , -CO2R 9 , -C(0)NR 9 R 1 ', -C(S)NR 9 R", -C(NH)NR 9 R 11 , -SO2R 10 ,
- each R 9 and R" are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, -R 10 cycloalkyl, -R 10 0H,
- each R 10 is the same or different and is independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;
- Ay is aryl;
- Het is a 5- or 6-membered heterocyclic or heteroaryl group;
- n is 0, 1 or 2;
- Y is N or CH;
- R 2 is selected from the group consisting of Ay, Het, -OAy, -OHet, -OR 10 Ay, -0R 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0) ⁇ R 9 , -S(0)nAy, -R 10 NR 7 R 8 and -R 10 NR 7 Ay;
- R 3 and R 4 are the same or different and are each independently selected from the group consisting of H, halo, alkyl, alkenyl, cycloalkyl, Ay, Het, -C(0)R 7 , -C(0)Ay, -C0 2 R 7 , -C0_Ay, -OR 7 , -OAy, -0R 10 Ay, -0R 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -S0.NHR 9 , -R 10 OR 7 , -R 10 cycloalkyl, -R 10 OAy, -R 10 NR 7 R 8 and -R 10 NR 7 Ay; Ring A is selected from the group consisting of aryl, 5-10 membered heterocyclic group and a 5-10 membered heteroaryl group; q is 0, 1 , 2, 3, 4 or 5; each R 5 is the same or different and is independently selected from the group consisting of
- X is CI, Br or I; and M is-B(0H) 2 , -B(0Ra)z, -B(Ra)z, -Sn(Ra) 3 , Zn-halide, ZnRa, Mg-halide where Ra is alkyl or cycloalkyl and halide is halo.
- the process for preparing the compounds of formula (I) wherein p is 1 and R 1 is selected from the group consisting of Het, -OR 7 , -OAy, -OHet, -OR 10 Ay, -OR 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0) consentR 9 , -S(0) ⁇ Ay, -S(0)nHet and azido, (all formulas and all other variables having been defined above in connection with Scheme 1) comprises the steps of: a) reacting an aminopyrazole of formula (II) with a sodium salt of ethylformyl acetate of formula (III) to prepare a compound of formula (IV); b) treating the compound of formula (IV) with a chlorinating-dehydrating agent to prepare a compound of formula (V); c) halogenating the compound of formula (V) to prepare a compound of formula (V
- the reaction may be carried out in an inert solvent, in the presence of a palladium (0) or nickel (0) catalyst.
- the reaction may optionally be heated to about 50-150°C.
- the reaction is performed by reacting equimolar amounts of a compound of formula (VII) with a Het-metal compound of formula (VIII), but the reaction may also be performed in the presence of an excess of the compound of formula (VIII).
- the palladium or nickel catalyst is typically present in 1-10 mol% compared to the compound of formula (VII).
- Suitable palladium catalysts include but are not limited to, tetrakis(triphenylphosphine)palladium (0), dichlorobis(triphenyl- phosphine)palladium(ll), tris(dibenzylideneacetone)dipalladium (0), and bis(diphenylphosphinoferrocene)palladium (II) dichloride.
- Suitable solvents include but are not limited to, ⁇ /, ⁇ /-dimethylformamide, toluene, tetrahydrofu an, dioxane, and 1 -methyl-2-pyrrolidinone.
- Het-metal compound of formula (VIII) is an arylboronic acid or ester or an arylborinate the reaction is more conveniently carried out by adding a base in a proportion equivalent to, or greater than, that of the compound of formula (VII).
- Het-metal compounds of formula (VIII) may be obtained from commercial sources or prepared either as discreet isolated compounds or generated in situ using methods known to one skilled in the art. (Suzuki, A. J. Organomet Chem. 1999, 576, 147; Stille, J. Angew. Chem. Int. Ed. Engl. 1986, 25, 508; Snieckus, V. J. Org. Chem. 1995, 60, 292).
- a compound of formula (VII) can be prepared by reacting a compound of formula (VI) with a suitable nucleophile to provide compounds of formula (VII) wherein R 1' is selected from the group consisting of Het, -OR 7 , -OAy, -OHet, -OR 10 Ay, -0R 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0)nR 9 , -S(0)nAy, -S(0) respectfulHet and azido.
- R 1' is selected from the group consisting of Het, -OR 7 , -OAy, -OHet, -OR 10 Ay, -0R 10 Het, -NR 7 R 8 , -NR 7 Ay, -NHHet, -NHR 10 Ay, -NHR 10 Het, -S(0)nR 9 , -S(0)nAy
- a compound of formula (VI) can be treated with a nucleophile neat or the reaction can be carried out in an inert solvent at room temperature or optionally with heating to provide compound of formula (VII).
- Appropriate nucleophiles for substituting the group R 1' on the ring will be apparent to those skilled in the art of organic synthesis.
- a compound of formula (VI) can be prepared from a compound of formula (V) via a halogenation procedure.
- the halogenation reaction is carried out by treating the compounds of formula (V) with a halogenating agent in a suitable solvent.
- Suitable halogenating agents include but are not limited to, /V-bromosuccinimide, trialkylammonium tribromides, bromine, ⁇ /-chlorosuccinimide, /V-iodosuccinimide, iodine monochloride, and the like.
- Suitable solvents include, for example, ⁇ /./V-dimethylformamide, tetrahydrofuran, dioxane, 1-methyl-2-pyrrolidinone, carbon tetrachloride, toluene, dichloromethane, diethyl ether, and the like.
- a compound of formula (V) can be prepared from a compound of formula (IV).
- this type of transformation can be carried out using phosphorous oxychloride, optionally in the presence of a base.
- This is performed by treating a compound of formula (IV) with phosphorous oxychloride with optional heating.
- a compound of formula (IV) with phosphorous oxychloride with optional heating.
- an excess of the dehydrating reagent is used and the reaction can be heated up to reflux temperature of approximately 105 °C.
- a particular base is ⁇ /, ⁇ /-diethylaniline and the like.
- a compound of formula (IV) can be prepared from a compound of formula (II).
- the compounds of formula (I) and pharmaceutically acceptable salts, solvates and physiologically functional derivatives thereof may also be prepared using procedures analogous to those described in PCT Publication No. WO02/16359, published to GlaxoSmithKline Inc., the disclosure of which is incorporated herein by reference in its entirety.
- the preparation of compounds of formula (I) wherein the pyrazolo[1 ,5-a]pyrimidines are substituted at the C-7 position is shown in Scheme 1.
- condensation of an aminopyrazole with malonimidate gives 5,7- diaminosubstituted pyrazolo_1 ,5-a]pyrimidines [Arch. Pharm. 1985, 318:87-88) that can be elaborated into compounds of formula (I) using conditions similar to those in Scheme 1.
- Other disubstituted derivatives can be obtained as described in the literature [Farmaco, 1978, 33:14-20) and elaborated into compounds of formula (I) using the procedures described in Scheme 1 above.
- the palladium or nickel coupling reaction of the pyrazolo[l,5- alpyrim ' idine with the compound of formula (VIII) can be accomplished with pyrazolo[1,5-a]pyrimidines having any of various substitutions represented by (R 1 ) P in formula (I).
- the present invention also provides a process for preparing compounds of formula (I) which process comprises reacting a compound of formula (Vll-A) with a compound of formula (VIII)
- one method of converting a compound of formula (I) to another compound of formula (I) comprises a) oxidizing the compound of formula (l-A) to prepare a compound of formula (l-B) and then b) optionally reacting a compound of formula (l-B) with an oxygen or amine nucleophile selected from the group consisting of Het bonded through N, -OR 7 , -OAr, -OHet, -OR ,0 Het, -NR 7 R 8 , -NHHet, -NHR 10 Ay and -NHR 10 Het to produce a compound of formula (I) wherein R 2 is selected from the group consisting of Het bonded through N, -OR 7 , -OAr, -OHet, -OR 10 Het, -NR 7 R 8 , -NHHet, -NHR 10 Ay and -NHR 10 Het.
- R 2 is selected from the group consisting of Het bonded through N, -OR 7 , -OAr, -OHet, -OR 10 Het, -NR 7 R 8 , -NHHet, -NHR 10 Ay and -NHR 10 Het, n' is 1 or 2; and all other variables are as above.
- a compound of formula (I) can be prepared by reacting a compound of formula (l-B) (i.e., a compound of formula (I) wherein R 2 is -S(0)n'R 9 where n' is 1 or 2) with an oxygen or amine nucleophile selected from the group consisting of Het bonded through N, -OR 7 , -OAr, -OHet, -0R ,0 Het, -NR 7 R 8 , -NHHet, -NHR 10 Ay and -NHR 10 Het.
- the reaction may be carried out neat or in a suitable solvent and may be heated to 50-150°C.
- the solvent is a lower alcohol such as methanol, ethanol, isopropanol and the like or solvent such as ⁇ /, ⁇ /-dimethylformamide or tetrahydrofuran, and the like.
- a base may be used to facilitate the reaction.
- the base can be potassium carbonate, or an amine base such as triethylamine.
- a compound of the formula (l-B) may be conveniently prepared by reacting a compound of formula (l-A) (i.e., a compound of formula (I) wherein R 2 is -S(0)nR 9 where n is 0) with an oxidizing agent in an inert solvent, optionally in the presence of a base.
- Suitable solvents include but are not limited to, dichloromethane, chloroform and the like.
- Another particularly useful method for converting a compound of formula (I) to another compound of formula (I) comprises reacting a compound of formula (l-C) (i.e., a compound of formula (I) wherein R 2 is fluoro) with an amine nucleophile (including substituted amines, heterocycles and heteroaryls, particularly those linked through N), and optionally heating the mixture to 50-150°C to prepare a compound of formula (I- D) (i.e., a compound of formula (I) wherein R 2' is selected from the group consisting of Het, -NR 7 R 8 , -NHHet, -NHR 10 Ay and -NHR 10 Het).
- R 2' is selected from the group consisting of Het, -NR 7 R 8 , -NHHet, -NHR 10 Ay, and -NHR 10 Het all other variables are as defined above.
- This procedure may be carried out by mixing a compound of formula (l-C) in a neat amine, or in a suitable solvent with an excess of amine to produce a compound of formula (l-D).
- the solvent is a lower alcohol such as methanol, ethanol, isopropanol or the like.
- suitable solvents may include /V./V-dimethyl-formamide, 1-methyl-2-pyrrolidine and the like.
- a compound of formula (l-E) (i.e., where X 1 is halogen) may be converted to a compound of formula (l-F) using amination techniques known to those skilled in the art.
- X 1 is halo, such as chloro, bromo or iodo
- Amine is selected from the group consisting of Het bonded through N, -NR 7 R 8 ,
- the reaction can be carried out via an adaptation of procedures found in the literature (Wolfe, J. P.; Buchwald, S. L. J. Org. Chem. 2000, 65, 1144) wherein a compound of the formula (l-E) is treated with an amine, a palladium (0) or nickel (0) source and a base, optionally in a suitable solvent, at a temperature ranging from ambient temperature to 200 °C.
- Suitable sources of palladium (0) include but are not limited to palladium(ll) acetate and tris(dibenzylideneacetone) dipalladium (0).
- Typical bases for use in the reaction include, for example sodium fert-butoxide and cesium carbonate.
- the reaction can be carried out in neat amine or in a suitable solvent. Toluene is an example of a suitable solvent.
- a compound of formula (1-G) i.e., a compound of formula (I) wherein q is 1 or more and at least one R 5 is -O-methyl
- a compound of formula (l-H) i.e., a compound of formula (I) wherein q is 1 or more and at least one R 5 is -OH
- a compound of formula (l-H) may optionally be converted to a compound of formula (I- J) (i.e., a compound of formula (I) wherein q is 1 or more and at least one R 5 is -OR 10 ).
- the foregoing conversions are represented schematically as follows:
- q' is 1 , 2 or 3; Me is methyl, and all other variables are as defined above.
- the demethylation reaction may be carried out by treating a compound of formula (l- G) in a suitable solvent with a Lewis acid at a temperature of -78°C to room temperature, to produce a compound of formula (l-H).
- the solvent is an inert solvent such as dichloromethane, chloroform, acetonitrile, toluene or the like.
- the Lewis acid may be boron tribromide, trimethylsilyl iodide and the like.
- a compound of formula (l-H) may be further converted to a compound of formula (l-J) by an alkylation reaction.
- the alkylation reaction may be carried out by treating a compound of formula (l-H) in suitable solvent with an alkyl halide of formula R 10 -Halo where R 10 is as defined above, to form another compound of formula (l-J).
- the reaction is preferably carried out in the presence of a base and with optionally heating to 50-200°C.
- the reaction may be carried out in solvents such as N.N-dimethylformamide, dimethylsulfoxide and the like.
- the base is potassium carbonate, cesium carbonate, sodium hydride or the like. Additionally, as will be apparent to those skilled in the art, the alkylation reaction can be carried out under Mitsunobu conditions.
- reaction methods can also be used to convert a compound of formula (I) wherein at least one R 1 is -OMe to a compound of formula (I) wherein at least one R 1 is -OH or a compound of formula (I) wherein at least one R 1 is -OR 10 .
- the foregoing methods are employed to make the same conversion when R 3 or R 4 is -OMe, to prepare a compound of formula (I) wherein R 3 or R 4 is -OH or a compound of formula (I) wherein R 3 or R 4 is -OR 10 .
- a compound of formula (l-K) i.e., a compound of formula (I) wherein q is 1 or more and at least one R 5 is halo
- a compound of formula (l-M) i.e. a compound of formula (I) wherein q is 1 or more and at least one R s is nitro
- a compound of formula (l-L) i.e., a compound of formula (I) wherein q is 1 or more and at least one R s is -NH2
- a compound of formula (l-L) may then be converted to a compound of formula (l-N) (i.e., a compound of formula (I) wherein q is 1 or more and at least one R 5 is -NR 7 R 8 where R 7 and R 8 are not both H).
- a compound of formula (l-N) i.e., a compound of formula (I) wherein q is 1 or more and at least one R 5 is -NR 7 R 8 where R 7 and R 8 are not both H.
- the foregoing conversions are represented schematically as follows: cross coupling, reductive amination, alkylation, acetylation or sulfonation
- q' is 1, 2 or 3, and all other variables are as defined above.
- the imine is benzophenoneimine
- the palladium (0) source is tris(dibenzylideneacetone)dipalladium(0)
- the base is sodium fer -butoxide
- the ligand is r ⁇ cem/c-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl.
- Suitable solvents include ⁇ /,/V-dimethylformamide and the like.
- a compound of formula (l-L) can also be obtained from a compound of formula (l-M) by reduction.
- the reduction can conveniently be carried out by using zinc, tin or iron and acid, by using tin(ll)chloride, or by using palladium or platinium catalysts under hydrogen atmosphere in a suitable solvent as will be apparent to those skilled in the art of organic synthesis.
- Reaction of a compound of formula (l-L) with a compound of formula R 7 -halogen in a suitable solvent in the presence of base, optionally with heating may be used to prepare a compound of formula (1-N).
- the base is triethylamine or pyridine and the solvent is N.N-dimethylformamide and the like.
- Additional compounds of formula (l-N) can be obtained by reductive animation of a compound of formula (l-L) with a ketone or aldehyde. See, A. Abdel-Magid, et al., J. Org. Chem. 61 .3849-3862 (1996).
- a compound of formula (l-L) is treated with an aldehyde or a ketone in the presence of an acid, such as acetic acid, and a reducing agent, such as sodium triacetoxyborohydride or the like, in an inert solvent such as dichloroethane or the like.
- reaction methods can also be used to convert a compound of formula (1) wherein at least one R 1 is halo to a compound of formula (I) wherein at least one R 1 is -NH 2 and a compound of formula (I) wherein at least one R 6 is -NR 7 R 8 (where R 7 and R 8 are not both H).
- the foregoing methods are employed to make the same conversion when R 3 or R 4 is halo, to prepare a compound of formula (I) wherein R 3 or R 4 is -NH2 or a compound of formula (I) wherein R 3 or R 4 is -NR 7 R 8 (where R 7 and R 8 are not both H).
- Radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) can be prepared using conventional techniques.
- radiolabeled compounds of formula (I) can be prepared by reacting the compound of formula (I) with tritium gas in the presence of an appropriate catalyst to produce radiolabeled compounds of formula (1).
- the compounds of formula (I) are tritiated.
- the radiolabeled compounds of formula (I) and biotinylated compounds of formula (I) are useful in assays for the identification of compounds for the treatment or prophylaxis of viral infections such as herpes viral infections. Accordingly, the present invention provides an assay method for identifying compounds which have activity for the treatment or prophylaxis of viral infections such as herpes viral infections, which method comprises the step of specifically binding the radiolabeled compound of formula (I) or the biotinylated compounds of formula (I) to the target protein. More specifically, suitable assay methods will include competition binding assays.
- the radiolabeled compounds of formula (I) and biotinylated compounds of formula (1) can be employed in assays according to the methods conventional in the art.
- Example 1 3-(2-Fluoropyridin-4-yl)-2-phenyl-7-pyrrolidin-1-ylpyrazolo[l,5- ⁇ jpyrimidine.
- 3-Bromo-2-phenyl-7-pyrrolidin-1-ylpyrazolo[l,5- ⁇ ]pyrimidine 3-Bromo-7-chloro-2-phenylpyrazolo_1 ,5- ⁇ ]pyrimidine (100 mg, 0.32 mmol) was dissolved in ethanol. To this solution was added pyrrolidine (0.5 mL) and the reaction mixture heated at reflux for 10 minutes. The resulting mixture was concentrated in vacuo, then dissolved in dichloromethane and the organic phase was washed with water, dried over magnesium sulfate, filtered and concentrated.
- dichlorobis(tripenylphosphine)palladium (II) 60 mg, 0.09 mmol
- 2-fluoropyridin-4- ylboronic acid 92 mg, 0.66 mmol
- sodium carbonate 185 mg, 1.76 mmol
- the resulting solution was heated at 1 10 °C for 24 hours.
- the resulting mixture was diluted with dichloromethane and washed with water.
- the organic phase was dried over magnesium sulfate, filtered and concentrated.
- the resulting black residue was purified by silica gel chromatography (ethyl acetate:hexane 1 :1) to give 50 mg (32 %) of the title compound as a white solid.
- This solid was purified by silica gel chromatography (ethyl acetate:hexane 1 :1) to give 15 mg (25 %) of ⁇ /-cyclopentyl-4-(2-phenyl-7-pyrrolidin-1-ylpyrazolo[1,5- ⁇ ]pyrimidin-3-yl)pyridin- 2-amine as a foam and 4 mg (7 %) of ⁇ /-cyclopentyl-3-[2-(cyclopentylamino)pyridin- 4-yl]-2-phenylpyrazolo[! ,5- ⁇ ]pyrimidin-7-amine.
- Example 7 Biological Activity
- MEM Minimal Essential Media
- FBS Fetal Bovine Serum
- NP40 Fetal Bovine Serum
- Igepal are detergents
- MOI Multiplicity of Infection
- NaOH sodium hydroxide
- MgC magnesium chloride
- dATP means deoxyadenosine 5' triphosphate
- dUTP means deoxyuridine 5' triphosphate
- dCTP means dexoxycytidine 5' triphosphate
- dGTP means deoxyguanosine 5' triphosphate
- GuSCN Guanidinium thiocyanate
- EDTA means ethylenediamine tetraacetic acid
- TE means Tris-EDTA
- SCC sodium chloride/sodium citrate
- APE means a solution of ammonia acetate, ammonia phosphate, EDTA
- PBS means phosphate buffered saline
- APE means a solution of ammonia acetate, ammonia
- Cell lysates are prepared as follows: media was removed and replaced with 150 ⁇ L/well 0.2 N NaOH with 1% Igepal CA 630 or NP-40. Plates were incubated up to 14 days at room temperature in a humidified chamber to prevent evaporation.
- a gel-purified, digoxigenin-labeled, 710-bp PCR fragment of the HSV UL-15 sequence was utilized.
- PCR conditions included 0.5 ⁇ M primers, 180 ⁇ M dTTP, 20 ⁇ M dUTP-digoxigenin (Boehringer Mannheim 1558706), 200 ⁇ M each of dATP, dCTP, and dGTP, 1X PCR Buffer II (Perkin Elmer), 2.5 mM MgCb, 0.025 units/ ⁇ L of AmpliTaq Gold polymerase (Perkin Elmer), and 5 ng of gel-purified HSV DNA per 100 ⁇ L Extension conditions were 10 min at 95°C, followed by 30 cycles of 95°C for 1 min, 55°C for 30 sec, and 72°C for 2 min.
- the amplification was completed with a 10- min incubation at 72°C.
- Primers were selected to amplify a 728 bp probe spanning a section of the HSV1 UL15 open reading frame (nucleotides 249-977).
- Single-stranded transcripts were purified with Promega M13 Wizard kits.
- the final product was mixed 1 :1 with a mixture of 6 M GuSCN, 100 mM EDTA and 200 ⁇ g/ml herring sperm DNA and stored at 4°C.
- Hybridization Twenty-seven (27) ⁇ L of cell lysate was combined with 45 ⁇ L of hybridization solution (final concentration: 3M GuSCN, 50 mM EDTA, 100 ⁇ g/ml salmon sperm DNA, 5X Denhardt's solution, 0.25X APE, and 5 ng of the digoxigenin-labeled detection probe).
- APE is 1.5 M NH 4 -acetate, 0.15 M NH 4 H 2 phosphate, and 5 mM EDTA adjusted to pH 6.0.
- Mineral oil 50 ⁇ L was added to prevent evaporation. The hybridization plates were incubated at 95°C for 10 minutes to denature the DNA, then incubated at 42°C overnight.
- the wells were washed 6X with 300 ⁇ L/well SSC/T buffer then incubated with 75 ⁇ L/well anti-digoxigenin- HRP-conjugated antibody (Boehringer Mannheim 1207733, 1 :5000 in TE) for 30 min at room temperature.
- the wells were washed 6X with 300 ⁇ L/well with PBS/0.05% Tween-20 before 75 ⁇ L/well SuperSignal LBA substrate (Pierce) was added.
- the plates were incubated at room temperature for 30 minutes and chemiluminescence was measured in a Wallac Victor reader. e) Results.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60314623T DE60314623T2 (en) | 2002-05-10 | 2003-04-30 | SUBSTITUTED PYRAZOLOPYRIMIDINES |
EP03726540A EP1504004B1 (en) | 2002-05-10 | 2003-04-30 | Substituted pyrazolopyrimidines |
AU2003228770A AU2003228770A1 (en) | 2002-05-10 | 2003-04-30 | Substituted pyrazolopyrimidines |
US10/512,916 US7304068B2 (en) | 2002-05-10 | 2003-04-30 | Substituted pyrazolo [1,5-A] pyrimidinyls and pharmaceutical uses therefore |
JP2004503469A JP2005529919A (en) | 2002-05-10 | 2003-04-30 | Therapeutic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37942102P | 2002-05-10 | 2002-05-10 | |
US60/379,421 | 2002-05-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003095455A2 true WO2003095455A2 (en) | 2003-11-20 |
WO2003095455A3 WO2003095455A3 (en) | 2003-12-24 |
Family
ID=29420528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/013395 WO2003095455A2 (en) | 2002-05-10 | 2003-04-30 | Substituted pyrazolopyrimidines |
Country Status (8)
Country | Link |
---|---|
US (1) | US7304068B2 (en) |
EP (1) | EP1504004B1 (en) |
JP (1) | JP2005529919A (en) |
AT (1) | ATE365740T1 (en) |
AU (1) | AU2003228770A1 (en) |
DE (1) | DE60314623T2 (en) |
ES (1) | ES2287476T3 (en) |
WO (1) | WO2003095455A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069838A1 (en) * | 2003-02-10 | 2004-08-19 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7247626B2 (en) | 2002-03-07 | 2007-07-24 | Smithkline Beecham Corporation | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7491829B2 (en) | 2005-02-04 | 2009-02-17 | Array Biopharma Inc. | RAF inhibitor compounds and methods |
EP2308866A1 (en) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazoles and their use as fungicides |
WO2011076725A1 (en) | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
WO2011163518A1 (en) * | 2010-06-24 | 2011-12-29 | Gilead Sciences, Inc. | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
EP2402337A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402343A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole-fused bicyclic compounds |
EP2402345A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
EP2402344A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
WO2013050434A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
WO2013050437A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
WO2013096681A1 (en) * | 2011-12-22 | 2013-06-27 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
US8507472B2 (en) | 2010-04-07 | 2013-08-13 | Bayer Cropscience Ag | Bicyclic pyridinylpyrazoles |
US8633198B1 (en) * | 2011-09-20 | 2014-01-21 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
US8980878B2 (en) | 2012-04-17 | 2015-03-17 | Gilead Sciences, Inc. | Compounds and methods for antiviral treatment |
AU2015200638B2 (en) * | 2010-06-24 | 2016-11-10 | Gilead Sciences, Inc. | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
US9969687B2 (en) | 2013-12-23 | 2018-05-15 | Norgine B.V. | Compounds useful as CCR9 modulators |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2859729B1 (en) * | 2003-09-12 | 2006-02-24 | Roquette Freres | AQUEOUS DISPERSIONS OF AT LEAST ONE BIODEGRADABLE POLYMER |
CA2939036C (en) * | 2013-12-11 | 2020-09-22 | Nant Holdings Ip, Llc | Pyrazolopyrimidine derivatives useful in the treatment of influenza a and other rna viruses |
US9963455B2 (en) * | 2014-01-22 | 2018-05-08 | Curovir Ab | Pyrazolo[1,5-a]pyrimidines as antiviral compounds |
US9981976B2 (en) * | 2014-12-08 | 2018-05-29 | Janssen Sciences Ireland Uc | Piperidine substituted pyrazolo[1,5-A]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) |
WO2020092314A1 (en) | 2018-10-30 | 2020-05-07 | Kronos Bio, Inc. | Compounds, compositions, and methods for modulating cdk9 activity |
EP4262792A1 (en) * | 2020-12-18 | 2023-10-25 | The Scripps Research Institute | Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531901A2 (en) * | 1991-09-09 | 1993-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity |
WO1998052937A2 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11505524A (en) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | Imidazo 1,2-A pyridine and imidazo 1,2-A pyrididine derivatives and their use as bone resorption inhibitors |
US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
US6124289A (en) | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
JP2000038350A (en) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | Diabetes therapeutic drug |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
PE20020506A1 (en) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS |
GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
-
2003
- 2003-04-30 AU AU2003228770A patent/AU2003228770A1/en not_active Abandoned
- 2003-04-30 US US10/512,916 patent/US7304068B2/en not_active Expired - Fee Related
- 2003-04-30 WO PCT/US2003/013395 patent/WO2003095455A2/en active IP Right Grant
- 2003-04-30 AT AT03726540T patent/ATE365740T1/en not_active IP Right Cessation
- 2003-04-30 DE DE60314623T patent/DE60314623T2/en not_active Expired - Fee Related
- 2003-04-30 ES ES03726540T patent/ES2287476T3/en not_active Expired - Lifetime
- 2003-04-30 JP JP2004503469A patent/JP2005529919A/en active Pending
- 2003-04-30 EP EP03726540A patent/EP1504004B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531901A2 (en) * | 1991-09-09 | 1993-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity |
WO1998052937A2 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247626B2 (en) | 2002-03-07 | 2007-07-24 | Smithkline Beecham Corporation | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them |
US8586576B2 (en) | 2002-09-04 | 2013-11-19 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
WO2004069838A1 (en) * | 2003-02-10 | 2004-08-19 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7354929B2 (en) | 2003-04-23 | 2008-04-08 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7491829B2 (en) | 2005-02-04 | 2009-02-17 | Array Biopharma Inc. | RAF inhibitor compounds and methods |
US7994185B2 (en) | 2008-05-06 | 2011-08-09 | Glaxo Smith Kline LLC | Benzene sulfonamide thiazole and oxazole compounds |
US8415345B2 (en) | 2008-05-06 | 2013-04-09 | Glaxo SmithKline LLC | Benzene sulfonamide thiazole and oxazole compounds |
EP2784072A1 (en) | 2009-10-09 | 2014-10-01 | Bayer CropScience AG | 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides |
EP2784071A1 (en) | 2009-10-09 | 2014-10-01 | Bayer CropScience AG | 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides |
EP2784070A1 (en) | 2009-10-09 | 2014-10-01 | Bayer CropScience AG | 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides |
EP2784073A1 (en) | 2009-10-09 | 2014-10-01 | Bayer CropScience AG | 3-phenyl-4-pyri(mi)dinyl-1h-pyrazoles and their use as fungicides |
WO2011042389A2 (en) | 2009-10-09 | 2011-04-14 | Bayer Cropscience Ag | Phenylpyri(mi)dinylazoles |
EP2308866A1 (en) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazoles and their use as fungicides |
WO2011076725A1 (en) | 2009-12-21 | 2011-06-30 | Bayer Cropscience Ag | Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi |
US8685974B2 (en) | 2009-12-21 | 2014-04-01 | Bayer Cropscience Ag | Thienylpyri(mi)dinylazole |
US8507472B2 (en) | 2010-04-07 | 2013-08-13 | Bayer Cropscience Ag | Bicyclic pyridinylpyrazoles |
AU2011270798B2 (en) * | 2010-06-24 | 2015-03-19 | Gilead Sciences, Inc. | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
KR101970837B1 (en) | 2010-06-24 | 2019-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
US9957275B2 (en) | 2010-06-24 | 2018-05-01 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines for antiviral treatment |
US8486938B2 (en) | 2010-06-24 | 2013-07-16 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines for antiviral treatment |
CN102958933A (en) * | 2010-06-24 | 2013-03-06 | 吉里德科学公司 | Pyrazolo [1, 5 -A] pyrimidines as antiviral agents |
AU2015200638B2 (en) * | 2010-06-24 | 2016-11-10 | Gilead Sciences, Inc. | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
EA023223B1 (en) * | 2010-06-24 | 2016-05-31 | Джилид Сайэнс, Инк. | PYRAZOLO[1,5-a]PYRIMIDINES FOR ANTIVIRAL TREATMENT |
KR20140032333A (en) * | 2010-06-24 | 2014-03-14 | 길리애드 사이언시즈, 인코포레이티드 | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
EP3012258A1 (en) * | 2010-06-24 | 2016-04-27 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines and -triazines as antiviral agents |
US8809330B2 (en) | 2010-06-24 | 2014-08-19 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines for antiviral treatment |
CN105481866A (en) * | 2010-06-24 | 2016-04-13 | 吉里德科学公司 | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
CN102958933B (en) * | 2010-06-24 | 2016-02-03 | 吉里德科学公司 | As pyrazolo [1, the 5-A] miazines of antiviral drug |
US9238039B2 (en) | 2010-06-24 | 2016-01-19 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines for antiviral treatment |
AP3417A (en) * | 2010-06-24 | 2015-09-30 | Gilead Sciences Inc | Pyrazolo [1,5-a] pyrimidines as antiviral agents |
WO2011163518A1 (en) * | 2010-06-24 | 2011-12-29 | Gilead Sciences, Inc. | Pyrazolo [1, 5 -a] pyrimidines as antiviral agents |
EP2402344A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
EP2402337A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402343A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole-fused bicyclic compounds |
EP2402345A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
WO2012175513A1 (en) | 2011-06-20 | 2012-12-27 | Bayer Intellectual Property Gmbh | Thienylpyri(mi)dinylpyrazole |
US8633198B1 (en) * | 2011-09-20 | 2014-01-21 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
US9987282B2 (en) | 2011-09-20 | 2018-06-05 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
US9422291B2 (en) | 2011-09-20 | 2016-08-23 | Nant Holdings Ip, Llc | Small molecule inhibitors of influenza A RNA-dependent RNA polymerase |
WO2013050434A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
CN104039785A (en) * | 2011-10-06 | 2014-09-10 | 拜耳知识产权有限责任公司 | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
US9023844B2 (en) | 2011-10-06 | 2015-05-05 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
WO2013050437A1 (en) | 2011-10-06 | 2013-04-11 | Bayer Intellectual Property Gmbh | Heterocyclylpyri (mi) dinylpyrazole as fungicidals |
US9278975B2 (en) | 2011-12-22 | 2016-03-08 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines as antiviral agents |
AU2012358805B2 (en) * | 2011-12-22 | 2017-07-20 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
WO2013096681A1 (en) * | 2011-12-22 | 2013-06-27 | Gilead Sciences, Inc. | Pyrazolo[1,5-a]pyrimidines as antiviral agents |
US8946238B2 (en) | 2011-12-22 | 2015-02-03 | Gilead Sciences, Inc. | Pyrazolo[1,5-A]pyrimidines as antiviral agents |
US8980878B2 (en) | 2012-04-17 | 2015-03-17 | Gilead Sciences, Inc. | Compounds and methods for antiviral treatment |
US9504689B2 (en) | 2012-04-17 | 2016-11-29 | Gilead Sciences, Inc. | Compounds and methods for antiviral treatment |
US10174038B2 (en) | 2012-04-17 | 2019-01-08 | Gilead Sciences, Inc. | Compounds and methods for antiviral treatment |
US9969687B2 (en) | 2013-12-23 | 2018-05-15 | Norgine B.V. | Compounds useful as CCR9 modulators |
Also Published As
Publication number | Publication date |
---|---|
DE60314623D1 (en) | 2007-08-09 |
ES2287476T3 (en) | 2007-12-16 |
WO2003095455A3 (en) | 2003-12-24 |
EP1504004A2 (en) | 2005-02-09 |
US7304068B2 (en) | 2007-12-04 |
US20050203106A1 (en) | 2005-09-15 |
EP1504004B1 (en) | 2007-06-27 |
AU2003228770A1 (en) | 2003-11-11 |
AU2003228770A8 (en) | 2003-11-11 |
JP2005529919A (en) | 2005-10-06 |
DE60314623T2 (en) | 2008-02-28 |
ATE365740T1 (en) | 2007-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1504004B1 (en) | Substituted pyrazolopyrimidines | |
EP1385847B1 (en) | Pyrazolo[1,5-a]pyridine derivatives | |
EP1377575B1 (en) | Antiviral pyrazolopyridine compounds | |
EP1341788B1 (en) | Pyrazolopyridines | |
EP1401836B1 (en) | Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections | |
US7153863B2 (en) | Therapeutic compounds based on pyrazolopyridline derivatives | |
EP1432712B1 (en) | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection | |
EP1372643A1 (en) | Pyrazolopyridines, process for their preparation and use as therapeutic compounds | |
EP1423389A1 (en) | Pyrazolo-pyridines for the treatment of herpes infections | |
EP1485385B1 (en) | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | |
EP1453830B1 (en) | Pyrazolo-pyridine derivatives as antiherpes agents | |
AU2002312459A1 (en) | Imidazo`1,2-A!pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10512916 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003726540 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004503469 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003726540 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003726540 Country of ref document: EP |